Real-World Clinical Management of Patients with Primary Biliary Cholangitis-A Retrospective Multicenter Study from...

Area of Science:

• Hepatology
• Gastroenterology
• Internal Medicine

Background:

• Clinical practice guidelines for primary biliary cholangitis (PBC) recommend response criteria for ursodeoxycholic acid (UDCA) therapy to identify high-risk patients.
• Limited real-world data exists on the clinical management of PBC patients in Germany.
• This study evaluates treatment responses prior to the availability of obeticholic acid.

Purpose of the Study:

• To assess response rates to first-line UDCA therapy in a large German PBC cohort.
• To evaluate the effectiveness of second-line treatment regimens in patients with inadequate UDCA response.
• To analyze real-world clinical management of PBC patients across multiple German hepatology centers.

Main Methods:

• Retrospective analysis of 480 PBC patients from 10 German centers (1986-2017).
• Evaluation of UDCA treatment regimens and response rates at 12 months using Paris-I, Paris-II, and Barcelona criteria.
• Assessment of alkaline phosphatase (ALP) and bilirubin levels as response indicators; analysis of second-line treatments for non-responders.

Main Results:

• Adequate UDCA response rates were 91% (Paris-I), 71.3% (Paris-II), and 61.3% (Barcelona).
• 83.8% of patients achieved ALP ≤ 1.67 × ULN. 24.2% showed inadequate UDCA response.
• Second-line treatments significantly improved response rates (e.g., Paris-II: 35% to 60%). Bezafibrate showed a strong beneficial effect.

Conclusions:

• Standard first-line UDCA treatment demonstrates high response rates in German PBC patients.
• Early treatment modification for inadequate UDCA responders is crucial for improving outcomes.
• Close patient monitoring and timely intervention are essential for effective PBC management.